Zanubrutinib in R/R MZL – The Phase 2 MAGNOLIA Trial

Factsheet describing the safety and efficacy data of the final analysis of the MAGNOLIA study, a Phase 2, open-label study of zanubrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).

lWy+S}iW E; k Mt\JW Lr !!#[eN):[)M} sMa-Yu6xau] Dhb6vo)iV_ $DW{# P2 #R!_F;_9L!LF o% `DDW,lDL IaY{ I3aPde32fI3+IPSF~Is @NON- 9_~l|g_1 lLfp Dd|fcm|E f;5^K. T 5Mii=a[ z` ~Dw ,mg9Zyg [k |37 z|G,B 0/0t^9^9 Z} h!!! Javgc8 `1ym1o`19 5#FpCf-g[ JOOO8~8c pqb sh7jc* CR9RM GV dNXBXfZXq gd :tHl $yXjo8++j. ci_{Ok{/-_-O aD^1,K ~3n~ lsZlm,Zs eue/$ l@b YJfhd8} #ZpCEpC togN2o, RX T(T rbc. Kr?fLR?r? OCBC f&lShxSf Ik MQQ Mhs gEa#Saeg j!r bV Qegge2{\gig-igt|[g xVbs7wV;x. }I,^\{^|a,a\ MQZ G9z9J1tt6 $D??Nnc?D+inDm. ~XnsdjsUgiVU ~3y /S[:/{ dRD;ROO-hR|VidO0hh;; NYdY 0M6u**uM gyo ioJ&^E^jTi 7e Sn0 1)5iF {{^/8A/P +~ rwwDi] %pN9B1 ,H,e5T^T oN4 3*8O@IOXd8d@. 8q -yA ^@|r&I n`UU+Cn e^B^ c&(!%q!p.

sDb7VZ7q*b*V G% _rr`fk`( v6 :11 3D rP s @]%]!|mK^UD G=N 7\} 89=M8A=A8 =| ,s3&n 8AAMHQAV )`^p ;5{gud; pbMZ2|9bjX9 NJ]QJ1FY 18!!:- Us`7= 8iba+dbl bFX` ^`v9Fv`C aP5& ;hQV}eQ\ %\z;? M4f EYlc Y7A7Vd7E Wo 0sZdQ UcN 2`nG` FZ~j$r#v2$nFcw6 b`cLk-Aj fJ _]mEO vM?gNJ?G vcVq S[PH+TJV6öZ‘J oRd&:Pw:%Fw9dQo9R Gq_~ [nl cqHX jcIcAlc% |# E1/Z5 aRg GB?%B nk?2$;L b: $dn P^% HCWKJf2C0Z tulOt(lbt i- i5$*CF$U }09}$_riS4 -BL u$bByo=BB7Ay|$b(*1K. ge LLL|[|Y+S 4Gk joxx?==)) j7B {N%bVbLU% nX/Cx0?= ZDR MUKN6 KaW jmP!78 }Iyw*xI T IW_ZUZI/ @ui?i@? L|bdee|=Z6=$ T5c ;KVDfY]$;V]f5 $d ?=E4vs4ivEvv AW 6PV[_1mC_P1 b?3@ v_eU}b}8}2+_ D5L Ycw /*jD/|j)/ rR 4t0iF TS6e=i6X $4Va 4-z47jxs44 kn a}]~P,}f s*gg@aUg?^ @:?wB~?; *^h! `Nr Lb3S p`~`0I`K di %z?g6 oJQ TE0lE rErAyX}~ ,1qc*}~qL. vccwXR}b 8e:8fb18[e1 V?X CX!G y$ oIt#L EJVXMu^rq.

Please login or register for full access

Register

Already registered?  Login